New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy

- Real-world evidence reinforces TAILORx treatment paradigm and standard of care use for Oncotype DX test

- Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists

GENEVA, March 25, 2019 /PRNewswire/ -- New data recently presented at the 16th St. Gallen International Breast Cancer Conference further support the utility of Oncotype DX Breast Recurrence Score test to optimise chemotherapy recommendations in patients with early-stage breast cancer with or without lymph node involvement.

An updated analysis¹ of the Clalit Health Services registry, the largest health services organisation in Israel, examined medical records of more than 1,300 patients with node negative breast cancer applying the Recurrence Score cut point determined by the landmark TAILORx study². The findings showed that use of chemotherapy was aligned with Recurrence Score results and that patients with Recurrence Score results up to 25, the vast majority of whom were treated with hormonal therapy alone, had excellent outcomes at ten years with low rates of distant recurrence.

"This important analysis with long-term follow up is based on our experience with the Oncotype DX test in routine clinical practice and is consistent with findings from multiple clinical trials, including the TAILORx study", said Prof. Salomon Stemmer, lead investigator of the study, Department of Oncology, Davidoff Center, Rabin Medical Center affiliated to Tel Aviv University, Israel. "These results continue to show the unique value of adding genomic information provided by the test to better target chemotherapy."   

Another piece of research presented at the congress is real-world evidence³ from a study in more than 80,000 patients, based on an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registry programme of the National Cancer Institute (NCI). The findings confirmed that the Oncotype DX Breast Recurrence Score result is predictive of chemotherapy benefit in patients with node-negative disease (p=0.009), with no chemotherapy benefit in patients with Recurrence Score results up to 25. In patients with node-negative disease and Recurrence Score results up to 25 not treated with chemotherapy, the Breast Cancer Specific Survival (BCSS) was greater than 96 percent at nine years. In patients with node-positive disease not treated with chemotherapy and Recurrence Score results less than 18, BCSS was greater than 97 percent at nine years.